Phase 2 N=97 Pediatric Head Lice Study Product Comparison
Head Lice
Primary: Number of Participants Free of Live Head Lice and Free of Viable Eggs — 57; 55; 32; 46 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=558 Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice
Pediculosis
Primary: Efficacy of NatrOVA Creme Rinse - 1% Relative to NIX Creme Rinse in Subjects Infested With Head Lice — 77; 19; 40; 14 participants
Phase 3 N=480 Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice
Pediculus Capitis Infestation
Primary: Efficacy of NatrOVA Creme Rinse - 1% Relative to NIX Creme Rinse in Subjects Infested With Head Lice — 72; 17; 36; 11 participants
Phase 2 N=78 Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation
Pediculus Humanus Capitis (Head Lice)
Primary: Percentage of Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) — 56; 50…
Phase 3 N=118 Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands
Scabies · Head Lice
Primary: Number of Participants With Headlice — 3 Participants
Phase 3 N=371 A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects
Head Lice
Primary: Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) — 71…
Phase 3 N=410 A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation
Head Lice
Primary: Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) — 76…
Phase 3 N=911 Clinical Endpoint Study of Ivermectin 0.5% Lotion
Head Lice
Primary: Percentage of Index Participants Who Were Considered a Treatment Success: PP Population — 90.9; 89.0 percentage of participants
Phase 2 N=247 Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects
Head Lice
Primary: Percentage of Participants With Treatment Success Following Treatment With Either Ivermectin or Placebo (Vehicle Control) — 95; 53; 83; 49 Percent of Participants
Phase 2 N=142 An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation
Pediculosis
Primary: Number of Participants Who Are Lice Free at All Follow-up Visits (Day 1, 7 and 14) Through the Day 14 Visit — 31; 42; 11 participants — p=<0.001
Phase 4 N=26 Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation
Pediculosis
Primary: Cmax for Spinosyn A — NA ng/mL
N/A N=100 A Clinical Trial Evaluating the Efficacy of Resultz Lice and Egg Elimination Kit on Pediatric and Adult Subjects
Pediculus Capitis
Primary: The Total Number of Lice + Eggs Removed From the Head After One Hour of Combing — 71.3; 26.1 number of lice and eggs removed — p=<0.0001
Phase 2 N=50 Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation
Head Lice Infestation
Primary: Percentage of Hatched Eggs Pre Treatment Relative to Post Treatment — -92.9; -42.3 Percent hatched eggs post versus pre Rx
Phase 2 N=47 Neem Lotion With Combing for Lice
Pediculoses · Head Lice
Primary: Number of Participants Free From Head Louse Infestation as Assessed by Detection Combing — 23; 22 Participants
Phase 3 N=254 Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
Pediculosis
Primary: Proportion of Index Subjects Free of Any of Lice 14 Days After Their Last Treatment. — 82.98; 62.50 percentage of subjects — p=0.0386
Phase 3 N=403 Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
Pediculosis
Primary: Proportion of Index Subjects Free of Any Lice 14 Days After Their Last Treatment in the Modified ITT (LOCF) — 86.67; 45.33 percentage of subjects — p=<0.0001
Phase 2 N=230 A Study Evaluating the Safety and Efficacy of BGC20-0582 Lice Treatment Gel for Head Lice Infestation
Pediculus Humanus Capitis · Head Lice
Primary: Clinical Cure — 30; 28; 35; 32 Participants
Phase 2 N=77 Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult
Dermatitis, Seborrheic · Dry Skin; Eczema
Primary: Efficacy Determined Using the Investigator's Global Assessment (IGA) - Adult — 2.1; 1.1 units on a scale — p=<0.001
Phase 3 N=296 A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice
Head Lice
Primary: The Proportion of Index Subjects Who Are Lice Free at Day 15 — 106; 98; 7 Participants
Phase 2 N=38 Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation
Head Lice Infestation
Primary: Number of the Subjects With AEs. — 8 participants
Phase 4 N=58 A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation
Pediculosis Capitis · Lice Infestations · Head Lice
Primary: Proportion of Participants Who Are Completely Free of Live Lice — 0.00; 0.00; .535; .200 proportion of subjects free of live lice — p=.025
Phase 3 N=379 A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation
Head Lice Infestation
Primary: Proportion of Index Subjects Who Are Lice-free at All Follow-up Visits Through to the Day 14 Visit. — 43; 28 participants
N/A N=42 Efficacy and Safety of Licefreee Spray Against Nix 1% Permethrin
Pediculosis Capitis
Primary: The Proportion Within Each Treatment Group of Subjects Who Have no Live Lice — 17; 9 participants
Phase 1 N=30 A Pharmacokinetics (PK) Study in Lice Infested Children 6 Months to 3 Years of Age
Head Lice
Primary: Mean Plasma Concentration of Ivermectin in Samples Collected Before Application and at Specified Post-Application Time Points — 0.00000; 0.02528; 0.08192; 0.20075 ng/mL
N/A N=70 A Clinical Trial to Evaluate Efficacy and Safety of a Water-soluble Head Lice Product.
Head Lice · Pediculosis Capitis
Primary: Number of Subjects That Are Lice-free After 2 Treatments With Test Product (Including All Baseline Infestations). — 30; 30 Participants — p=0.023
Phase 3 N=12 Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
Pediculosis
Primary: Participants With a Change in Cholinesterase Level at 1 Hour (Day 0). — -1.8; -0.5 percentage change in cholinesterase
Phase 3 N=239 Bioequivalence Study for Benzyl Alcohol Lotion 5%.
Head Lice
Primary: Number of Participants With Infestation Successfully Eliminated by Active Treatment. — 59; 57; 6 Participants
Phase 3 N=219 Subject Preference for Scalp Psoriasis Treatment
Scalp Psoriasis
Primary: Percentage of Subjects Preffering Clobetasol Propionate Shampoo Better Than Comparator — 28.5; 31.6; 21.8 Percentage of participants — p=0.0003
Phase 3 N=254 Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies
Scabies
Primary: Number of Patients in Each Treatment Group With Therapeutic Cure (Parasitological Cure Plus Clinical Cure) of Scabies — 83; 86 Participants
Phase 4 N=42 Promiseb Topical Cream for Cradle Cap
Cradle Cap · Infantile Seborrheic Dermatitis
Primary: Subjects With Investigator Global Assessment (IGA) Success (IGA of 0 or 1) at End of Treatment (Day 7 or 14). — 91.7; 96 percentage of participants — p=>0.05